It was shown that local delivery of aCTLA-4 Abs through Montanide ISA-51 as a slow-release mechanism in the mice-bearing tumor could provide immune responses (higher CD8+ T cells) tumor eradication in low dosages of the drug. The gene discussed is CD8A; the disease is neoplasm.